Siji Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Siji Chen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Hao Cheng
Department of Dermatology and Venereology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
3 shared publications Xia Wu
Department of Dermatology and Venereology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China
2 shared publicationsXiaoyun Jiang
Department of Dermatology and Venereology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China
2 shared publicationsCan Zhou
Department of Dermatology School of Medicine Sir Run Run Shaw Hospital Zhejiang University Hangzhou People's Republic of China
1 shared publicationChunting Hua
Department of Dermatology School of Medicine Sir Run Run Shaw Hospital Zhejiang University Hangzhou People's Republic of China
1 shared publication- Jiang Zhu
Department of Dermatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou 310016, China
1 shared publication
Latest Publications
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 15779-15785
Successful Treatment of Severe and Refractory Eosinophilic Pustular Folliculitis with Dupilumab: A Case Report with Two-Year Relapse-Free Follow-Up
Background: Eosinophilic pustular folliculitis (EPF) is a rare chronic inflammatory skin disease characterized by eosinophilic infiltration and recurrent sterile pustules. Current treatments are often ineffective, and the disease frequently relapses. Methods: We report a case of a 71-year-old female with severe EPF and a 17-year history of recurrent pruritic papulopustular eruptions. Dupilumab was administered subcutaneously with a 600 mg loading dose followed by 300 mg every two weeks over two treatment courses, separated by a five-month loss to follow-up. Results: After dupilumab therapy, the patient’s skin lesions completely resolved, accompanied by a marked decrease in peripheral eosinophil counts. During a 2-year follow-up, no recurrence was observed. Conclusion: Dupilumab demonstrated significant efficacy and safety in this severe and refractory EPF case, resulting in long-term remission without relapse, and highlighting its potential as a novel treatment option for EPF.
- 1 November 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 15779-15785
Open AccessSuccessful Treatment of Severe and Refractory Eosinophilic Pustular Folliculitis with Dupilumab: A Case Report with Two-Year Relapse-Free Follow-Up
Background: Eosinophilic pustular folliculitis (EPF) is a rare chronic inflammatory skin disease characterized by eosinophilic infiltration and recurrent sterile pustules. Current treatments are often ineffective, and the disease frequently relapses. Methods: We report a case of a 71-year-old female with severe EPF and a 17-year history of recurrent pruritic papulopustular eruptions. Dupilumab was administered subcutaneously with a 600 mg loading dose followed by 300 mg every two weeks over two treatment courses, separated by a five-month loss to follow-up. Results: After dupilumab therapy, the patient’s skin lesions completely resolved, accompanied by a marked decrease in peripheral eosinophil counts. During a 2-year follow-up, no recurrence was observed. Conclusion: Dupilumab demonstrated significant efficacy and safety in this severe and refractory EPF case, resulting in long-term remission without relapse, and highlighting its potential as a novel treatment option for EPF.
- Open Access
- 1 May 2023
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 17, 1593-1609
0.5–5% Supramolecular Salicylic Acid Hydrogel is Safe for Long-Term Topical Application and Improves the Expression of Genes Related to Skin Barrier Homeostasis in Mice Models
Background: As a keratolytic, salicylic acid (SA) can be topically applied in various formulations and doses in dermatology. Supramolecular SA hydrogel, a new SA formulation with higher bioavailability, is developed and commercially available nowadays. However, there still remain concerns that the long-term and continual application of SA at low concentrations may jeopardize the cutaneous barrier properties. Aim of the Study: To reveal the long-term effects of 0.5– 5% supramolecular SA hydrogel on the skin barrier in normal mice models. Materials and Methods: The 0.5%, 1%, 2%, and 5% supramolecular SA hydrogel or hydrogel vehicle without SA was applied to mice’s shaved dorsal skin once per day respectively. Tissue samples of the dorsal skin were harvested on day 14 and 28 of the serial application of SA for histopathological observation and transcriptomic analysis. Results: Following topical supramolecular SA hydrogel therapy with various concentrations of SA (0.5%, 1%, 2%, and 5%) for 14 days and 28 days, there were no obvious macroscopic signs of impaired cutaneous health and no inflammatory or degenerative abnormalities were observed in histological results. Additionally, the transcriptomic analysis revealed that on day 14, SA dramatically altered the expression of genes related to the extracellular matrix structural constituent. And on day 28, SA regulated gene expression profiles of keratinization, cornified envelope, and lipid metabolism remarkably. Furthermore, the expression of skin barrier related genes was significantly elevated after the application of SA based on RNA-seq results, and this is likely to be associated with the PPAR signaling pathway according to the enrichment analysis. Conclusion: Our findings demonstrated that the sustained topical administration of the 0.5– 5% supramolecular SA hydrogel for up to 28 days did no harm to normal murine skin and upregulated the expression of genes related to the epidermal barrier.
- 1 May 2023
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 17, 1593-1609
Open Access0.5–5% Supramolecular Salicylic Acid Hydrogel is Safe for Long-Term Topical Application and Improves the Expression of Genes Related to Skin Barrier Homeostasis in Mice Models
Background: As a keratolytic, salicylic acid (SA) can be topically applied in various formulations and doses in dermatology. Supramolecular SA hydrogel, a new SA formulation with higher bioavailability, is developed and commercially available nowadays. However, there still remain concerns that the long-term and continual application of SA at low concentrations may jeopardize the cutaneous barrier properties. Aim of the Study: To reveal the long-term effects of 0.5– 5% supramolecular SA hydrogel on the skin barrier in normal mice models. Materials and Methods: The 0.5%, 1%, 2%, and 5% supramolecular SA hydrogel or hydrogel vehicle without SA was applied to mice’s shaved dorsal skin once per day respectively. Tissue samples of the dorsal skin were harvested on day 14 and 28 of the serial application of SA for histopathological observation and transcriptomic analysis. Results: Following topical supramolecular SA hydrogel therapy with various concentrations of SA (0.5%, 1%, 2%, and 5%) for 14 days and 28 days, there were no obvious macroscopic signs of impaired cutaneous health and no inflammatory or degenerative abnormalities were observed in histological results. Additionally, the transcriptomic analysis revealed that on day 14, SA dramatically altered the expression of genes related to the extracellular matrix structural constituent. And on day 28, SA regulated gene expression profiles of keratinization, cornified envelope, and lipid metabolism remarkably. Furthermore, the expression of skin barrier related genes was significantly elevated after the application of SA based on RNA-seq results, and this is likely to be associated with the PPAR signaling pathway according to the enrichment analysis. Conclusion: Our findings demonstrated that the sustained topical administration of the 0.5– 5% supramolecular SA hydrogel for up to 28 days did no harm to normal murine skin and upregulated the expression of genes related to the epidermal barrier.
- Open Access
- 2 January 2023
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 19 (1) , 2151290
The complicated use of dupilumab in the treatment of atypical generalized pemphigus erythematosus: A report of two cases
Pemphigus is a rare autoimmune disease and has the potential to be fatal without treatment. Pemphigus erythematosus (PE) is a benign type of pemphigus foliaceus. Glucocorticoids and immunosuppressive agents are primary therapeutic modalities in pemphigus erythematosus, which may lead to considerable side effects. There is a growing need for new pemphigus therapies with fewer adverse effects. Dupilumab is a humanized monoclonal IgG4 antibody that inhibits the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) and has been applied for atopic dermatitis and asthma. Recently, dupilumab was thought to be beneficial in aggressive refractory pemphigus vulgaris. We report two cases: a 39-year-old male and a 59-year-old woman diagnosed with PE with atypical clinical features. With dupilumab, patients’ skin lesions significantly improved, and suitable maintenance glucocorticosteroid doses were reached. In conclusion, we reported the short-term effectiveness and safety of dupilumab in two cases of atypical generalized PE. As an adjunct, such a biologic agent is expected to be efficacious in pemphigus erythematosus.
- 2 January 2023
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 19 (1) , 2151290
Open AccessThe complicated use of dupilumab in the treatment of atypical generalized pemphigus erythematosus: A report of two cases
Pemphigus is a rare autoimmune disease and has the potential to be fatal without treatment. Pemphigus erythematosus (PE) is a benign type of pemphigus foliaceus. Glucocorticoids and immunosuppressive agents are primary therapeutic modalities in pemphigus erythematosus, which may lead to considerable side effects. There is a growing need for new pemphigus therapies with fewer adverse effects. Dupilumab is a humanized monoclonal IgG4 antibody that inhibits the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) and has been applied for atopic dermatitis and asthma. Recently, dupilumab was thought to be beneficial in aggressive refractory pemphigus vulgaris. We report two cases: a 39-year-old male and a 59-year-old woman diagnosed with PE with atypical clinical features. With dupilumab, patients’ skin lesions significantly improved, and suitable maintenance glucocorticosteroid doses were reached. In conclusion, we reported the short-term effectiveness and safety of dupilumab in two cases of atypical generalized PE. As an adjunct, such a biologic agent is expected to be efficacious in pemphigus erythematosus.